BUSINESS
    Marubeni Pharma Seeks New Growth Drivers to Hit FY2035 Sales Goal
    By Hayate Horiguchi July 10, 2026
    Marubeni Pharmaceuticals must secure new growth drivers as quickly as possible if it is to achieve its goal of lifting annual sales above 100 billion yen by FY2035, President and COO Shigeyuki Nishinaka told Jiho,…

    LATEST

    Women Hold Nearly 1/4 of Leadership Roles at Japan’s Listed Pharmas and Wholesalers
    July 10, 2026
    Women now account for nearly one in four statutory corporate officer positions at Japan’s listed pharmaceutical companies and wholesalers, according to a Jiho survey, reflecting steady progress toward the government’s 30% goal for female leadership.The…
    FIRM Backs Growth Roadmap, Expects Better Investment Climate
    July 10, 2026
    The Forum for Innovative Regenerative Medicine (FIRM) has welcomed the Japanese government’s public-private investment roadmap, expressing hope that it will help create a more favorable long-term investment environment for the regenerative medicine industry.“Regenerative medicine has…
    JPMA Sees Honebuto Shifting toward Industry Promotion, Still Against Off-Year Cuts
    July 10, 2026
    The Japan Pharmaceutical Manufacturers Association (JPMA) has hailed the pharmaceutical-related provisions in the government’s draft “honebuto” policy for 2026, saying they are more closely aligned with the industry’s innovation agenda than in previous years.Speaking at…

    Chuikyo Debate on FY2026 Drug Pricing Reform

    Romiplate to See Steepest Cut in April Market Expansion Re-Pricing

    Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

    COMMENTARY

    DORA Use Could Expand as Japan Opens Door to “Sleep Disorders” Specialty
    By Shinya Sato

    Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…

    COLUMN

    The Psychology of ‘Stuck’: Understanding Why Changing Jobs Feels So Hard
    By Philip Carrigan

    Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…

    Drug Approval & Reimbursement in 2025

    Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen

    Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

    Chuikyo Debate on Off-Year Drug Price Revisions

    MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
    By Ken Yoshino

    The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

    Discussions on Next PMD Act Amendment

    Japan Cabinet Approves Bill to Amend PMD Act

    The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

    Drug Approval & Reimbursement in 2024

    Japan Approves Zepbound, Qalsody, and Lots More Drugs

    Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

    Chuikyo on FY2024 Reimbursement Reform

    Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap

    Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA